Clinical Trials
OTEZLA (Apremilast) Phase III Data Showed good results among Patients with Active Behçet’s Disease with Oral Ulcers
Celgene Corporation announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet's Disease with oral ulcers...
News
Bristol-Myers Squibb and Nektar Therapeutics to collaborate for Nektar’s CD122-biased Agonist, NKTR-214
Bristol-Myers Squibb Company announced the companies have executed a global strategic development and commercialization collaboration for Nektar’s lead immuno-oncology program, NKTR-214. ...
White Papers
Process Considerations for Cryogenic and Regenerative Medicine Commercialization
McKesson, Fisher BioServices, GE Healthcare and Cryoport are proud to announce our first annual workshop. Our FREE two-day workshop will provide a forum for...
News
Saneca Pharma appoints new CEO
Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král. Richard, who has...
Press Releases
Amgen sets up a FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO
Amgen announced that the Oncologic Drugs Advisory Committee of the U.S. FDA will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA)...
Press Releases
AbbVie presents New, Late Breaking Investigational Data at 2018 at AAD Annual meeting
AbbVie a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA® (adalimumab) at the...
News
AbbVie raises dividend and buys $10 billion of shares
AbbVie Inc (ABBV.N) said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read